hy-10191 Search Results


linsitinib  (MedChemExpress)
94
MedChemExpress linsitinib
Trop2 bound with IGF2R to activate <t>IGF2-IGF1R-Akt</t> axis in NSCLC gefitinib resistance. (A) Cells were transfected with shNC, shTrop2, and/or shIGF2R plasmids respectively with gefitinib treatment for 72 h to detect the proliferation ability. Mean ± SD, **P <0.01, means compared with shNC group, ## P <0.01, means compared with PC-9/GR shTrop2 group. (B) Cells were transfected with vector, OE-Trop2, and/or shIGF2R plasmids respectively for 72 h to detect the proliferation ability. Mean ± SD, ** P <0.01, means compared with vector group, ## P <0.01, means compared with PC-9/GR OE-Trop2 group. (C) PC-9/GR was knocked down or over-expressed with shIGF2R or linstinib for 24 h, Western blotting was used detect the protein level of p -IGF1R, Akt and p -Akt. (D-G) The migration of cells were detected through migration assay, and the representative images of cell migration were shown in (D) and (F), (E) is the statistical graph of (D), and (G) is the statistical graph of (F), Mean ± SD, *P <0.05, **P< 0.01.
Linsitinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/linsitinib/product/MedChemExpress
Average 94 stars, based on 1 article reviews
linsitinib - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
linsitinib (#hy-10191)  (Cedarlane)
90
Cedarlane linsitinib (#hy-10191)
Trop2 bound with IGF2R to activate <t>IGF2-IGF1R-Akt</t> axis in NSCLC gefitinib resistance. (A) Cells were transfected with shNC, shTrop2, and/or shIGF2R plasmids respectively with gefitinib treatment for 72 h to detect the proliferation ability. Mean ± SD, **P <0.01, means compared with shNC group, ## P <0.01, means compared with PC-9/GR shTrop2 group. (B) Cells were transfected with vector, OE-Trop2, and/or shIGF2R plasmids respectively for 72 h to detect the proliferation ability. Mean ± SD, ** P <0.01, means compared with vector group, ## P <0.01, means compared with PC-9/GR OE-Trop2 group. (C) PC-9/GR was knocked down or over-expressed with shIGF2R or linstinib for 24 h, Western blotting was used detect the protein level of p -IGF1R, Akt and p -Akt. (D-G) The migration of cells were detected through migration assay, and the representative images of cell migration were shown in (D) and (F), (E) is the statistical graph of (D), and (G) is the statistical graph of (F), Mean ± SD, *P <0.05, **P< 0.01.
Linsitinib (#Hy 10191), supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/linsitinib (#hy-10191)/product/Cedarlane
Average 90 stars, based on 1 article reviews
linsitinib (#hy-10191) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Trop2 bound with IGF2R to activate IGF2-IGF1R-Akt axis in NSCLC gefitinib resistance. (A) Cells were transfected with shNC, shTrop2, and/or shIGF2R plasmids respectively with gefitinib treatment for 72 h to detect the proliferation ability. Mean ± SD, **P <0.01, means compared with shNC group, ## P <0.01, means compared with PC-9/GR shTrop2 group. (B) Cells were transfected with vector, OE-Trop2, and/or shIGF2R plasmids respectively for 72 h to detect the proliferation ability. Mean ± SD, ** P <0.01, means compared with vector group, ## P <0.01, means compared with PC-9/GR OE-Trop2 group. (C) PC-9/GR was knocked down or over-expressed with shIGF2R or linstinib for 24 h, Western blotting was used detect the protein level of p -IGF1R, Akt and p -Akt. (D-G) The migration of cells were detected through migration assay, and the representative images of cell migration were shown in (D) and (F), (E) is the statistical graph of (D), and (G) is the statistical graph of (F), Mean ± SD, *P <0.05, **P< 0.01.

Journal: Journal of Cancer

Article Title: Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment

doi: 10.7150/jca.57711

Figure Lengend Snippet: Trop2 bound with IGF2R to activate IGF2-IGF1R-Akt axis in NSCLC gefitinib resistance. (A) Cells were transfected with shNC, shTrop2, and/or shIGF2R plasmids respectively with gefitinib treatment for 72 h to detect the proliferation ability. Mean ± SD, **P <0.01, means compared with shNC group, ## P <0.01, means compared with PC-9/GR shTrop2 group. (B) Cells were transfected with vector, OE-Trop2, and/or shIGF2R plasmids respectively for 72 h to detect the proliferation ability. Mean ± SD, ** P <0.01, means compared with vector group, ## P <0.01, means compared with PC-9/GR OE-Trop2 group. (C) PC-9/GR was knocked down or over-expressed with shIGF2R or linstinib for 24 h, Western blotting was used detect the protein level of p -IGF1R, Akt and p -Akt. (D-G) The migration of cells were detected through migration assay, and the representative images of cell migration were shown in (D) and (F), (E) is the statistical graph of (D), and (G) is the statistical graph of (F), Mean ± SD, *P <0.05, **P< 0.01.

Article Snippet: Linsitinib (IGF1R inhibitor) was purchased from MedChemExpress co., LTD (USA) and gefitinib was purchased from Astrazeneca LTD (England).

Techniques: Transfection, Plasmid Preparation, Western Blot, Migration

Trop2 activated IGF2 to reshape tumor microenvironment in NSCLC gefitinib resistance. (A-B) Co-culture system through migration assay, Wi38 or THP-1 cells were added in upper chamber, and PC-9/GR, PC-9/GR shTrop2 or PC-9/GR shTrop2+shIGF2R were added in lower chamber with gefitinib treatment for 24 h or 48 h; (A) Representative images of the cell migration were shown; (B) is the statistical graph of (A). (C) The protein levels of IGF2 and IGF1R were detected at 48 h in Wi38 and THP-1 cells. (D-E) The mRNA levels of IGF2 and IGF1R at 24 h in Wi38 and THP-1 cells. Mean ± SD, *P <0.05, **P <0.01, ***P< 0.001.

Journal: Journal of Cancer

Article Title: Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment

doi: 10.7150/jca.57711

Figure Lengend Snippet: Trop2 activated IGF2 to reshape tumor microenvironment in NSCLC gefitinib resistance. (A-B) Co-culture system through migration assay, Wi38 or THP-1 cells were added in upper chamber, and PC-9/GR, PC-9/GR shTrop2 or PC-9/GR shTrop2+shIGF2R were added in lower chamber with gefitinib treatment for 24 h or 48 h; (A) Representative images of the cell migration were shown; (B) is the statistical graph of (A). (C) The protein levels of IGF2 and IGF1R were detected at 48 h in Wi38 and THP-1 cells. (D-E) The mRNA levels of IGF2 and IGF1R at 24 h in Wi38 and THP-1 cells. Mean ± SD, *P <0.05, **P <0.01, ***P< 0.001.

Article Snippet: Linsitinib (IGF1R inhibitor) was purchased from MedChemExpress co., LTD (USA) and gefitinib was purchased from Astrazeneca LTD (England).

Techniques: Co-Culture Assay, Migration

Knockdown of Trop2 reduced gefitinib drug resistance combining with inhibiting IGF1R in vivo. (A) Nude mice bearing PC-9/GR shNC or shTrop2 cell lines xenograft tumors were treated with or without linstinib, companied with gefitinib oral administration. At the end of experiment, representative tumors were harvested, every animals were monitored for the change of tumors volume, Mean ± SD, *p < 0.05, **p < 0.01. (B) At the end, H&E staining of the tumor samples from mice were performed (amplification ×4, inside the box: amplification ×20). (C) Paraffin sections of some xenograft tumors were immune-stained with several antibodies. (D) Schematic overview of Trop2 in the crosstalk with IGF2-IGF1R-Akt axis between cancer cells and TME in the gefitinib resistance of NSCLCs.

Journal: Journal of Cancer

Article Title: Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment

doi: 10.7150/jca.57711

Figure Lengend Snippet: Knockdown of Trop2 reduced gefitinib drug resistance combining with inhibiting IGF1R in vivo. (A) Nude mice bearing PC-9/GR shNC or shTrop2 cell lines xenograft tumors were treated with or without linstinib, companied with gefitinib oral administration. At the end of experiment, representative tumors were harvested, every animals were monitored for the change of tumors volume, Mean ± SD, *p < 0.05, **p < 0.01. (B) At the end, H&E staining of the tumor samples from mice were performed (amplification ×4, inside the box: amplification ×20). (C) Paraffin sections of some xenograft tumors were immune-stained with several antibodies. (D) Schematic overview of Trop2 in the crosstalk with IGF2-IGF1R-Akt axis between cancer cells and TME in the gefitinib resistance of NSCLCs.

Article Snippet: Linsitinib (IGF1R inhibitor) was purchased from MedChemExpress co., LTD (USA) and gefitinib was purchased from Astrazeneca LTD (England).

Techniques: Knockdown, In Vivo, Staining, Amplification